Arteriovenous Malformations, Cerebral
Conditions
Keywords
Unruptured brain arteriovenous malformation, AVM, BAVM, Stroke, Intracranial Hemorrhage
Brief summary
The purpose of this study is to determine if medical management is better than invasive therapy for improving the long-term outcome of patients with unruptured brain arteriovenous malformations.
Detailed description
Brain arteriovenous malformations (BAVMs) are an infrequent but important cause of stroke, particularly in a young population. Current invasive treatment strategies are varied and include endovascular procedures, neurosurgery, and radiotherapy. All of these treatments are administered on the assumption that they can be achieved at acceptably minor complication rates, decrease the risk of subsequent hemorrhage, and lead to better long-term outcomes. Recent data from the literature comparing initial presentation and outcome for patients with ruptured and unruptured BAVMs have raised the possibility that such elective invasive treatment for unruptured BAVMs may yield worse outcomes than managing patients symptomatically with therapy. Unfortunately, no controlled clinical trials have yet been undertaken for management of unruptured BAVMs to address these concerns. Therefore, the goal of this randomized controlled trial is to determine if the long-term outcomes of patients who receive medical management for symptoms (e.g., headache, seizures) associated with an unruptured BAVM are superior to those who receive medical management and invasive therapy to eradicate the BAVM. Participants will be randomly assigned to receive either symptomatic medical management alone or such management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy). Functional assessment will be carried out at the time of randomization, pre-intervention and 48-hour post-intervention, and for all participants at 1 month, and at 6 month intervals throughout the follow up period which will be a minimum of 5 years.
Interventions
PROCEDUREInterventional therapy
All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
OTHERMedical management
Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
Columbia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient must have unruptured BAVM diagnosed by MRI/MRA, CTA and/or angiogram 2. Patient must be 18 years of age or older 3. Patient must have signed Informed Consent, Release of Medical Information, and Health Insurance Portability and Accountability Act (HIPAA/U.S. only) Forms
Exclusion criteria
1. Patient has BAVM presenting with evidence of recent or prior hemorrhage 2. Patient has received prior BAVM therapy (endovascular, surgical, radiotherapy) 3. Patient has BAVM deemed untreatable by local team, or has concomitant vascular or brain disease that interferes with/or contraindicates any interventional therapy type (stenosis/occlusion of neck artery, prior brain surgery/radiation for other reasons) 4. Patient has baseline Rankin ≥2 5. Patient has concomitant disease reducing life expectancy to less than 10 years 6. Patient has thrombocytopenia (\< 100,000/μL), 7. Patient has uncorrectable coagulopathy (INR\>1.5) 8. Patient is pregnant or lactating 9. Patient has known allergy against iodine contrast agents 10. Patient has multiple-foci BAVMs 11. Patient has any form of arteriovenous or spinal fistulas Previous diagnosis of any of the following - 12. Patient has a diagnosed Vein of Galen type malformation 13. Patient has a diagnosed cavernous malformation 14. Patient has a diagnosed dural arteriovenous fistula 15. Patient has a diagnosed venous malformation 16. Patient has a diagnosed neurocutaneous syndrome such as cerebro-retinal angiomatosis (von Hippel-Lindau), encephalo-trigeminal syndrome (Sturge-Weber), or Wyburn-Mason syndrome 17. Patient has diagnosed BAVMs in context of moya-moya-type changes 18. Patient has diagnosed hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference of 5-year event rates between two arms | 5 years | The hypothesis to be tested is that there is no difference between medical management and interventional therapy in the time to stroke or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of the risk of death or clinical impairment at 5 years post-randomization with early intervention | 5 years | The hypothesis to be tested is that early intervention decreases the risk of death or clinical impairment at 5 years post-randomization. (Rankin Score \>/= 2) |
Countries
Australia, Austria, Brazil, Canada, Finland, France, Germany, Italy, Netherlands, South Korea, Spain, Switzerland, United Kingdom, United States
Outcome results
None listed